2026 Nobel Prize in Chemistry: Kagan and Soai Solve the Mystery of Chirality

The 2026 Nobel Prize in Chemistry goes to Henri B. Kagan and Kenso Soai for discovering non-linear effects and autocatalysis in asymmetric organic synthesis—the chemical foundation for making single-enantiomer drug molecules, directly relevant to CDMOs and the pharmaceutical industry.

The 2026 Nobel Prize in Chemistry has been awarded to French scientist Henri B. Kagan and Japanese scientist Kenso Soai for discovering non-linear effects and autocatalysis in asymmetric organic synthesis. Many molecules—such as amino acids—exist as two mirror-image forms, yet living organisms typically contain only one of them. This phenomenon, called “homochirality,” long puzzled chemists.

In 1986, Kagan discovered non-linear effects in asymmetric reactions, allowing one mirror-image form to predominate far beyond what had been thought possible. Soai went further, discovering asymmetric autocatalysis—where the product itself acts as a catalyst, driving the formation of more of the same handedness—and in 2003 achieved a reaction that produced only a single mirror-image form.

For drug discovery and CDMO manufacturing, the ability to reliably produce single-enantiomer (chiral) active pharmaceutical ingredients is essential: the two mirror-image forms of a molecule can interact with the human body in completely different ways—one may heal, the other may harm. The laureates’ discoveries are now widely applied in organic synthesis and pharma, forming a core basis of modern chiral API processes.

Kagan and Soai have provided a solution to a chemical mystery that is over a century old: how homochirality can emerge spontaneously. The chemical reactions they have developed are spectacular.